Drug Trial Radar · NCT06879067
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Nov 12, 2018
Primary completion
Jul 23, 2019
Study completion Nov 9, 2020
Sponsor
- Lead sponsor
- Tiziana Life Sciences LTDIndustry
- Sponsor type
- Industry
- First posted
- Mar 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.
Conditions
- Safety
- Tolerability
Interventions
PlaceboDrug
Placebo nasal spray
Foralumab NasalDrug
foralumab nasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety- Adverse EventsTime frame: Day 1 vs End of Study (Day 30)
- Immune EffectTime frame: Dat 1 vs End of Study (Day 30)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ann Romney Center for Neurologic Diseases
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.